Genetic variation in RNASEL associated with prostate cancer risk and progression.

TitleGenetic variation in RNASEL associated with prostate cancer risk and progression.
Publication TypeJournal Article
Year of Publication2010
AuthorsMeyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, Fiorentino M, Finn S, Flavin RJ, Kurth T, Price AL, Giovannucci EL, Fall K, Stampfer MJ, Ma J, Mucci LA
JournalCarcinogenesis
Volume31
Issue9
Pagination1597-603
Date Published2010 Sep
ISSN1460-2180
KeywordsAdult, Aged, Aged, 80 and over, C-Reactive Protein, Case-Control Studies, Disease Progression, Endoribonucleases, Genotype, Humans, Interleukin-6, Male, Middle Aged, Mutation, Missense, Neoplasm Staging, Polymorphism, Single Nucleotide, Prospective Studies, Prostatic Neoplasms
Abstract

Variation in genes contributing to the host immune response may mediate the relationship between inflammation and prostate carcinogenesis. RNASEL at chromosome 1q25 encodes ribonuclease L, part of the interferon-mediated immune response to viral infection. We therefore investigated the association between variation in RNASEL and prostate cancer risk and progression in a study of 1286 cases and 1264 controls nested within the prospective Physicians' Health Study. Eleven single-nucleotide polymorphisms (SNPs) were selected using the web-based 'Tagger' in the HapMap CEPH panel (Utah residents of Northern and Western European Ancestry). Unconditional logistic regression models assessed the relationship between each SNP and incident advanced stage (T(3)/T(4), T(0)-T(4)/M(1) and lethal disease) and high Gleason grade (>/=7) prostate cancer. Further analyses were stratified by calendar year of diagnosis. Cox proportional hazards models examined the relationship between genotype and prostate cancer-specific survival. We also explored associations between genotype and serum inflammatory biomarkers interleukin-6 (IL-6), C-reactive protein (CRP) and tumor necrosis factor-alpha receptor 2 using linear regression. Individuals homozygous for the variant allele of rs12757998 had an increased risk of prostate cancer [AA versus GG; odds ratio (OR): 1.63, 95% confidence interval (CI): 1.18-2.25), and more specifically, high-grade tumors (OR: 1.90, 95% CI: 1.25-2.89). The same genotype was associated with increased CRP (P = 0.02) and IL-6 (P = 0.05) levels. Missense mutations R462Q and D541E were associated with an increased risk of advanced stage disease only in the pre-prostate-specific antigen era. There were no significant associations with survival. The results of this study support a link between RNASEL and prostate cancer and suggest that the association may be mediated through inflammation. These novel findings warrant replication in future studies.

DOI10.1093/carcin/bgq132
Alternate JournalCarcinogenesis
PubMed ID20576793
Grant ListCA-40360 / CA / NCI NIH HHS / United States
CA-34944 / CA / NCI NIH HHS / United States
HL-34595 / HL / NHLBI NIH HHS / United States
HL-26490 / HL / NHLBI NIH HHS / United States
T32 CA-09001 / CA / NCI NIH HHS / United States
CA-058684 / CA / NCI NIH HHS / United States
CA-097193 / CA / NCI NIH HHS / United States
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700